» Articles » PMID: 16510571

Cyclin D1 is Transcriptionally Regulated by and Required for Transformation by Activated Signal Transducer and Activator of Transcription 3

Overview
Journal Cancer Res
Specialty Oncology
Date 2006 Mar 3
PMID 16510571
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Signal transducers and activators of transcription 3 (STAT3) is a transcription factor that is aberrantly activated in many cancer cells. Constitutively activated STAT3 is oncogenic, presumably as a consequence of the genes that it differentially regulates. Activated STAT3 correlated with elevated cyclin D1 protein in primary breast tumors and breast cancer-derived cell lines. Cyclin D1 mRNA levels were increased in primary rat-, mouse-, and human-derived cell lines expressing either the oncogenic variant of STAT3 (STAT3-C) or vSrc, which constitutively phosphorylates STAT3. Mutagenesis of STAT3 binding sites within the cyclin D1 promoter and chromatin immunoprecipitation studies showed an association between STAT3 and the transcriptional regulation of the human cyclin D1 gene. Introduction of STAT3-C and vSrc into immortalized cyclin D1(-/-) and cyclin D1(-/+) fibroblasts led to anchorage-independent growth of only cyclin D1(-/+) cells. Furthermore, knockdown of cyclin D1 in breast carcinoma cells led to a reduction in anchorage-independent growth. Phosphorylation of the retinoblastoma (Rb) protein [a target of the cyclin D1/cyclin-dependent kinase 4/6 (cdk4/6) holoenzyme] was delayed in the cyclin D1(-/-) cells relative to cyclin D1(-/+) cells. The E7 oncogene, whose activity includes degradation of Rb and dissociation of Rb from E2F, did not confer anchorage-independent growth to the cyclin D1(-/-) cells but, in conjunction with vSrc, resulted in robust growth in soft agar. These results suggest both a cdk-dependent and cdk-independent role for cyclin D1 in modulating transformation by different oncogenes.

Citing Articles

Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer.

Rouault C, Bansard L, Martinez-Balsalobre E, Bonnet C, Wicinski J, Lin S Nat Commun. 2025; 16(1):2159.

PMID: 40038300 PMC: 11880418. DOI: 10.1038/s41467-025-57476-4.


Impact of G1 phase kinetics on the acquisition of stemness in cancer cells: the critical role of cyclin D.

Ahmadi Y, Faiq T, Abolhasani S Mol Biol Rep. 2025; 52(1):230.

PMID: 39951181 DOI: 10.1007/s11033-025-10351-3.


Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers.

Manore S, Zhuang C, Najjar M, Wong G, Bindal S, Watabe K Cells. 2025; 13(24).

PMID: 39768178 PMC: 11674475. DOI: 10.3390/cells13242087.


The MicroRNA miR-223 Constrains Colitis-associated Tumorigenesis by Limiting Myeloid Cell Infiltration and Chemokine Expression.

Flynn C, Markey G, Neudecker V, Farrelly C, Furuta G, Eltzschig H J Immunol. 2024; 213(12):1869-1883.

PMID: 39485006 PMC: 11611642. DOI: 10.4049/jimmunol.2400129.


Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.

Shi C, Bopp T, Lo H, Tkaczuk K, Lin J Curr Oncol. 2024; 31(10):5737-5751.

PMID: 39451730 PMC: 11505662. DOI: 10.3390/curroncol31100426.